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OBJECTIVE—To study insulin sensitivity and perfusion in
skeletal muscle together with the -cell function in subjects with
the m.3243AG mutation in mitochondrial DNA, the most com-
mon cause of mitochondrial diabetes.
RESEARCH DESIGN AND METHODS—We measured skele-
tal muscle glucose uptake and perfusion using positron emission
tomography and 2-[
18F]ﬂuoro-2-deoxyglucose and [
15O]H2O dur-
ing euglycemic hyperinsulinemia in 15 patients with m.3243AG.
These patients included ﬁve subjects with no diabetes as deﬁned
by the oral glucose tolerance test (OGTT) (group 1), three with
GHb 6.1% and newly found diabetes by OGTT (group 2), and
seven with a previously diagnosed diabetes (group 3). Control
subjects consisted of 13 healthy individuals who were similar to
the carriers of m.3243AG with respect to age and physical
activity. -Cell function was assessed using the OGTT and
subsequent mathematical modeling.
RESULTS—Skeletal muscle glucose uptake was signiﬁcantly
lower in groups 1, 2, and 3 than in the control subjects. The
glucose sensitivity of -cells in group 1 patients was similar to
that of the control subjects, whereas in group 2 and 3 patients,
the glucose sensitivity was signiﬁcantly lower. The insulin secre-
tion parameters correlated strongly with the proportion of
m.3243AG mutation in muscle.
CONCLUSIONS—Our ﬁndings show that subjects with m.3243A
G are insulin resistant in skeletal muscle even when -cell
function is not markedly impaired or glucose control compro-
mised. We suggest that both the skeletal muscle insulin sensitiv-
ity and the -cell function are affected before the onset of the
mitochondrial diabetes caused by the m.3243AG mutation.
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mpaired insulin sensitivity characterizes adult-onset
diabetes and has been attributed to decreased insu-
lin-stimulated glucose uptake in major metabolic
tissues such as skeletal muscle, liver, and adipose
tissue (1,2). It predicts diabetes strongly in subjects with
high hereditary risk (3). Decreased glucose uptake in
skeletal muscle is the major determinant of impaired
insulin sensitivity, because skeletal muscle is the tissue
that accounts for the majority of insulin-stimulated glu-
cose uptake in diabetes and in nondiabetic subjects (4).
Impaired insulin sensitivity has been correlated with de-
creased mitochondrial function and with decreased ex-
pression of genes involved in mitochondrial oxidative
phosphorylation in skeletal muscle (5,6). Interestingly,
similar ﬁndings in oxidative phosphorylation have recently
been made in healthy insulin-resistant subjects with high
hereditary predisposition for diabetes (7).
In addition to the impaired insulin sensitivity, a gradual
-cell failure is pivotal to the onset of diabetes in adult-
hood (8,9). It is noteworthy that most gene variants
associated with adult-onset diabetes inﬂuence the -cell
insulin secretion (10). Genes that contribute to mitochon-
drial oxidative phosphorylation are located both in the
nuclear DNA and in the maternally inherited mitochon-
drial DNA (mtDNA) (11). Intrinsic or acquired causes that
could impair oxidative phosphorylation in the mitochon-
drion have been proposed to impair both skeletal muscle
insulin sensitivity and -cell function (12,13).
The involvement of mtDNA mutations in the hereditary
forms of diabetes is evident (14,15). The mtDNA
m.3243AG mutation accounts for 1–2% of adult-onset
diabetes, and it has been estimated that most carriers of
this mutation develop diabetes during their adulthood
(16). This renders the m.3243AG mutation an interesting
pathogenic model for decreased mitochondrial function in
adult-onset diabetes. The m.3243AG mutation is hetero-
plasmic, i.e., the mutant allele and the wild-type allele
co-occur in mitochondria, and the proportion of mutated
mtDNA varies across patients and tissues (11). The hetero-
plasmy is known to modify the phenotype in patients with
m.3243AG (17), but previous studies on glucose metab-
olism have not included mutation heteroplasmy as a
variable. Furthermore, such studies have been small, so
that more than four subjects with m.3243AG have been
examined in only a few of them (18–24). Most of these
studies have revealed defects in insulin secretion (18–
21,24). Hyperinsulinemic clamp technique has been ap-
plied in only two previous studies on m.3243AG subjects,
but these studies could not identify peripheral insulin
resistance as the primary pathogenic factor (18,19).
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DIABETES, VOL. 58, MARCH 2009 543The aims of this study were 1) to characterize insulin
secretion and sensitivity in patients with a substantial
m.3243AG mutation load and in age-matched healthy
subjects, and 2) by using this disease model, to further
enlighten the role of mitochondria in the pathogenesis of
diabetes. We assessed whole-body glucose uptake by
using the hyperinsulinemic clamp technique together with
regional measurements of muscle perfusion and glucose
uptake by positron emission tomography (PET). Model-
based analysis of -cell function was carried out, and
measurements were correlated with mutation
heteroplasmy.
RESEARCH DESIGN AND METHODS
Fifteen patients with the m.3243AG mutation, most ascertained in a previous
epidemiological study (25), and 13 healthy control subjects were recruited. It
was required that the m.3243AG mutation heteroplasmy was 10%. Eight
patients had previously normal fasting glucose (group 1 and 2), and seven
patients had overt diabetes (group 3). The control subjects had normal
glucose tolerance. In the case of the control subjects, it was also required that
no diabetes was present in the ﬁrst-degree relatives before the age of 55 years.
All subjects were Finnish and in stable weight for the last 3 months before the
study. Written informed consent was obtained after the purpose, nature, and
potential risks were explained to the subjects. The study was approved by the
Ethics Committee of the Turku University Hospital.
Each subject underwent an oral glucose tolerance test (OGTT) on the ﬁrst
study day and indirect calorimetry and hyperinsulinemic-euglycemic clamp on
the second study day. Skeletal muscle glucose uptake and perfusion measure-
ments using PET and 2-[
18F]ﬂuoro-2-deoxyglucose and [
15O]H2O were per-
formed during the hyperinsulinemic-euglycemic clamp. All subjects were
instructed to avoid caffeine, smoking, alcohol, homeopathic preparations, and
changes in diet or in physical activity for 2 days before the study. All studies
were conducted after a 10-h fast and insulin cease. Metabolically active
substances except thyroid hormone were discontinued at least 24 h before the
studies (Table 1). Physical activity was assessed by a physical activity
questionnaire (International Physical Activity Questionnaire [IPAQ]) (26).
OGTT and assessment of -cell function. Subjects ingested 75 g glucose,
and blood samples were collected for glucose, insulin, and C-peptide at 0, 15,
30, 60, 90, and 120 min. The insulinogenic index (IGI), the ratio of the rise of
the insulin and glucose concentrations over basal level at 30 min, and the ratio
of insulin and glucose areas under the curve (AUCs) using trapezoidal
integration (AUCI/AUCG) were calculated. Mathematical modeling based on
C-peptide deconvolution (27) was used to describe insulin secretion as the
sum of two components as previously stated (28). The ﬁrst component, Sg(t),
represents the dependence on insulin secretion in absolute glucose concen-
tration (G) at any time point and is characterized by a dose-response function,
f(G). The slope of f(G) in the observed glucose range is denoted as -cell
glucose sensitivity. The dose-response function is modulated by a time-
dependent potentiation factor, P(t), accounting for several modulators of
insulin secretion (e.g., exposure to hyperglycemia, nonglucose substrates, and
gastrointestinal hormones); thus, Sg(t)  P(t)f(G). The increment of potenti-
ation during the OGTT was quantiﬁed as the ratio of the value of P(t)a tt h e
end of the test to that at baseline. The second insulin secretion component,
Sd(t), represents a dynamic dependence of insulin secretion, proportional to
the rate of change in glucose concentration. This proportionality constant is
termed rate sensitivity and is related to early insulin release (28). From the
model, the basal insulin secretion rate (pmol  min
1  m
2) was also
calculated.
Production of PET tracers. For production of [
15O] (t1/2  123 s), a
low-energy deuteron accelerator was used. [
15O] was produced in the
14N(d,n)
15O reaction using nitrogen gas as target material. Radiochemical
purity of [
15O]O2 exceeded 97%. [
15O]H2O was produced based on the
membrane technique using sterile exchangeable tubing in the device as
previously described (29). Sterility and pyrogenity tests were performed daily
to verify the purity of the product. [
18F]FDG (t1/2  110 min) was synthesized
with a computer-controlled apparatus according to a modiﬁed method of
TABLE 1
Subject characteristics
Control
subjects
m.3243AG mutation
Group 1 Group 2 Group 3
n 13 5 3 7
Clinical features
Men (n)2 0 0 4
Age (years) 47  3.0 48  4.0 46  5.1 46  4.6
BMI (kg/m
2) 24.1  0.8 25.9  1.2 23.9  2.2 20.6  1.2*
Physical activity (daily metabolic equivalent minutes) 442  79 655  115 548  157 351  58
Epithelial heteroplasmy (%) 0 33  10 47  35 3  4*
Muscle heteroplasmy (%) — 46  87 4  18 0  5*
Hearing aid (n)0 0 1 4
Duration of diabetes (years) — — 0 9.7  1.2
Medication
Insulin — — — 6/7
Metformin and nateglinide — — — 1/7
Statins — 1/5 — 4/7
-Blockers — 1/5 — 1/7
Thyroid hormone 1/13 2/5 — —
ACE inhibitors — 1/5 — 1/7
Valsartan — — — 2/7
Smokers 1/13 — 1/3 2/7
Metabolic characteristics
Fasting glucose (mmol/l) 5.2  0.1 5.4  0.1 6.0  0.3 9.2  0.8†‡§
Glycated hemoglobin (%) 5.4  0.1 5.4  0.2 6.0  0.1 7.7  0.4†*
Fasting insulin (pmol/l) 39  44 0  76 0  16 31  4¶*
Fasting C-peptide (nmol/l) 0.55  0.04 0.60  0.05 0.72  0.12 0.44  0.07
Fasting free fatty acids (mmol/l) 0.45  0.1 0.46  0.1 0.66  0.2 0.66  0.1
Uric acid (mol/l) 252  13 285  29 297  83 328  50
Creatine kinase (units/l) 91  8 116  48 164  83 155  32
Resting energy expenditure (kcal/min) 1.07  0.02 1.05  0.08 1.00  0.11 0.93  0.07
Resting energy expenditure (kcal  kg
1  min
1) 16  0.8 16  0.9 16  1.1 18  1.1
Data are means  SE. Comparisons between groups were made when overall P  0.05. A P value for signiﬁcant pairwise differences is given.
*P  0.05 vs. group 1. †P  0.001 vs. healthy subjects. ‡P  0.01 vs. group 1. §P  0.05 vs. group 2. ¶P  0.05 vs. healthy subjects.
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better than 70 GBq/mol, and the radiochemical purity exceeded 98%.
Image acquisition and hyperinsulinemic-euglycemic clamp. Subjects
were lying in the supine position during the PET study. At 0 min, a standard
primed hyperinsulinemic-euglycemic clamp (31) was started for at least 220
min using 1 mU  kg
1  min
1 intravenous insulin infusion. Normoglycemia
was maintained using variable rates of 20% glucose infusion, adjusted accord-
ing to plasma glucose. At 50 min, [
15O]H2O (0.5–0.8 GBq) was injected in over
30 s, and femoral muscle perfusion was measured with a dynamic 6-min scan
(6 5s ,6  15 s, and 8 30 s frames). To obtain the input function,
radioactivity was measured with a channel detector in arterial blood, with-
drawn with a pump at the rate of 6 ml/min. At 120 min, [
18F]FDG (0.23–0.29
GBq) was injected over 15 s, and a dynamic scan was started at 200 min
(frames 6 300 s). One of the subjects in group 1 failed to lie still during the
skeletal muscle glucose uptake measurement, and the data were not obtained.
Arterial blood samples were drawn after the [
18F]FDG injection, and radioac-
tivity was assessed with an automatic gamma counter. All the images were
acquired with a PET scanner that gives 35 transaxial planes with axial
resolution of 4.7 mm and in-plane resolution of 5.5 mm. The PET scanner and
other devices were cross-calibrated.
Measurement of skeletal muscle perfusion and glucose uptake. Radio-
activity was corrected for decay to the injection and expressed in kilobecque-
rels per milliliter. An autographic method was applied to calculate muscle
perfusion pixel by pixel (32). Data from [
18F]FDG images were reconstructed
to 128  128 pixel matrix using a planar Hann ﬁlter and an axial ramp ﬁlter.
A graphical model of [
18F]FDG kinetics was used as previously described (32).
The glucose uptake rate was obtained by multiplying the fractional rate of
tracer transport and phosphorylation (Ki) by the plasma glucose concentra-
tion after the [
18F]FDG injection and divided by lumped constant 1.2 as
previously validated for skeletal muscle (33). The lumped constant accounts
for the differences in the transport and phosphorylation between [
18F]FDG
and glucose. Glucose extraction was calculated by dividing the glucose uptake
with blood ﬂow. Regions of interest were drawn both in quadriceps femoris
and to hamstring muscles, carefully avoiding large blood vessels. The local-
ization of muscle compartments was veriﬁed by comparing [
18F]FDG and
[
15O]H2O images with the tissue density in transmission image.
Measurement of energy expenditure. The whole-body oxygen consump-
tion and the carbon dioxide production was measured in the fasting state with
an open-system indirect calorimeter in a quiet, dimly lit room. Resting energy
expenditure was calculated from a 10-min period after 20 min of initial
stabilization (34).
Measurement of the m.3243A>G mutation heteroplasmy. A buccal
epithelial cell sample was obtained from all the subjects (Table 1). The
mutation heteroplasmy in skeletal muscle was available for 12 of the 15
patients with m.3243AG (25). The m.3243AG mutation was detected by
cleavage of an ampliﬁed DNA fragment with the restriction enzyme Apa I. The
digested samples were electrophoresed, and the acrylamide gel was dried and
autoradiographed. The reproducibility was controlled by including, in each
electrophoresis run, a sample with the m.3243AG mutation (25).
Biochemical analyses. Plasma glucose was determined with a glucose
oxidase method. Plasma insulin and plasma C-peptide were assessed by
electrochemiluminescense immunoassay technique. Plasma creatine kinase
was determined with enzymatic method. Blood glycated hemoglobin was
measured with ion-exchange high-performance liquid chromatography. Serum
free fatty acid concentrations were measured via an enzymatic colorimetric
method.
Statistical methods. The results are expressed as means  SE. Before
analysis, the normality of variables was assessed by the Shapiro-Wilk test. The
differences among the group were identiﬁed using one-way ANOVA and
Tukey-Kramer post hoc procedure. Kruskall-Wallis nonparametric test was
used for group comparisons in continuous variables that were not normally
distributed. Post hoc tests were carried out by using Mann-Whitney U test, and
P values were corrected for multiple comparisons by the Benjamini-Hochberg
method (35). A P value of 0.05 was considered statistically signiﬁcant. Linear
correlations were assessed with Spearman’s correlation coefﬁcients.
RESULTS
Subject characteristics. Patients with m.3243AG were
divided into three groups based on the OGTT (Table 1).
Group 1 consisted of patients with either normal or
impaired glucose tolerance in OGTT (n  5). Patients in
group 2 had newly diagnosed diabetes that was detected
on the basis of high 2-h glucose in OGTT (n  3). Group 3
patients were all treated for diabetes that had been diag-
nosed previously (n  7). The three patient groups and the
control subjects were similar in age, physical activity, and
resting energy expenditure (Table 1). Furthermore, the
fasting plasma concentrations of C-peptide, uric acid,
creatine kinase, and serum free fatty acids were similar in
the four groups.
Insulin secretion and -cell function. All of the eight
subjects in groups 1 and 2 had good glycemic control (GHb
6.1%). During the ﬁrst 30 min of the OGTT, absolute
glucose, insulin, and C-peptide concentrations were iden-
tical in the control subjects and in group 1 patients, but at
120 min, plasma glucose was signiﬁcantly higher in group
1 patients and the insulin levels tended to surpass those
seen in the control subjects (Fig. 1). As a consequence, the
IGI and the rate sensitivity did not differ between these
two groups (Table 2). These two parameters describe the
rapid response of insulin secretion on the dynamic change
in glucose levels. Group 2 patients had the highest basal
insulin secretion rate, but the response to glucose load
was blunted as the decreased IGI indicated (Table 2).
The subjects in group 3 fulﬁlled the criteria for diabetes
both in the fasting state and at2hi nOGTT. Group 3
patients had signiﬁcantly lower insulin and C-peptide
already at 15 min of the OGGT than the control subjects
(Fig. 1). In consequence, the IGI was lower and the rate
sensitivity was strongly impaired compared with the con-
trol subjects and group 1 patients (Fig. 2).
In addition to the impaired rate sensitivity in group 3
patients, a mathematical modeling revealed that the -cell
glucose sensitivity was signiﬁcantly lower in group 2 and 3
patients than in the control subjects (dose-response func-
tion; Fig. 2). Furthermore, a low end period–to–start
period potentiation ratio was seen in group 3 patients
compared with the control subjects. Disposition index was
calculated by multiplying rate sensitivity with the whole-
body glucose uptake. It was similar in group 1 patients and
the control subjects, lower in group 2 patients than in the
control subjects, and signiﬁcantly lower in group 3 pa-
tients than in the control subjects or group 1 patients
(Table 2). These results imply that group 2 and group 3
patients were not able to raise their insulin secretion
during the OGTT in a similar manner as the control
subjects did.
Muscle glucose uptake and perfusion during the
hyperinsulinemic clamp. During the insulin infusion,
euglycemia was maintained in all groups with no differ-
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FIG. 1. OGTT in patients with the m.3243A>G mutation. A: Glucose
concentration. B: C-peptide concentration. C: Insulin concentration. E,
control subjects. Patients with m.3243A>G mutation: F, group 1; Œ,
group 2; and , group 3. A–C:* P < 0.05 vs. healthy subjects, at
respective time points.
M.M. LINDROOS AND ASSOCIATES
DIABETES, VOL. 58, MARCH 2009 545ence in the glucose or insulin concentrations. The rate of
insulin-stimulated glucose uptake was twofold higher in
the femoral skeletal muscle per unit tissue weight in the
control subjects than in group 1, 2, and 3 patients with
m.3243AG (Fig. 3). Consequently, the whole-body glu-
cose uptake (M value) measured as the glucose disposal
rate was signiﬁcantly lower in group 3 patients (Table 2)
and in the patients with no previously diagnosed diabetes
than in the control subjects (pooled groups 1 and 2 vs.
control subjects, P  0.030). A covariance analysis was
carried out to adjust for the variation in BMI between the
study groups. Analysis of the BMI-adjusted data did not
change the reported differences in the means of the
skeletal muscle and whole-body insulin sensitivity or in
the means of -cell rate and glucose sensitivity (data not
shown). Femoral muscle perfusion per tissue weight was
similar in all groups (Fig. 4), suggesting that muscle insulin
resistance was caused by decreased glucose extraction
rate in the patients with m.3243AG compared with the
control subjects (Fig. 4).
Heteroplasmy of the m.3243A>G mutation. Each sub-
ject in groups 1, 2, and 3 harbored at least 19% of the
m.3243AG mutation in buccal epithelium or skeletal
muscle. The mutation heteroplasmy in buccal epithelium
and skeletal muscle showed a good correlation (r  0.66,
P  0.019). AUCI/AUCG showed best negative linear
correlation with mutation heteroplasmy in skeletal muscle
(Fig. 5). This correlation was signiﬁcant even if the pa-
tients with previously diagnosed diabetes (group 3) were
excluded (r  0.71, P  0.02). Also, other parameters of
insulin secretion—IGI, glucose sensitivity, and rate sensi-
tivity—showed a signiﬁcant negative linear correlation
(r  0.66, P  0.02; r  0.81, P  0.001; and r  0.57,
P  0.05, respectively) with mutation heteroplasmy in
skeletal muscle. A negative linear correlation between rate
sensitivity and heteroplasmy in buccal epithelium was also
found (r  0.54, P  0.04). The whole-body or skeletal
muscle glucose uptake as well as the basal insulin secre-
tion did not show signiﬁcant relationship with the muta-
tion load in the m.3243AG carriers.
DISCUSSION
We found insulin resistance in the skeletal muscle already
in the early phase of glucose intolerance in subjects
harboring the m.3243AG mutation. The dynamic -cell
response was impaired in those mutation carriers who had
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FIG. 2. Rate sensitivity and glucose sensitivity of the -cells during
OGTT. A: Rate sensitivity is the insulin secretion response to the pace
of increase in plasma glucose. Control subjects, . Patients with
m.3243A>G mutation: z, group 1; t, group 2; and f, group 3. The
apparently high rate sensitivity in group 1 is partly due to the higher
insulin sensitivity in the control subjects, because rate sensitivity
tends to be inversely correlated with insulin sensitivity (see Table 2
for respective disposition index). B: Glucose sensitivity is the insulin
dose-response function to absolute glucose level during OGTT.
TABLE 2
Insulin sensitivity and -cell function in m.3243AG mutation
Study group
Control
subjects
m.3243AG mutation
Group 1 Group 2 Group 3
Insulin sensitivity
M value (mol  min
1  kg
1) 33  10 24  51 9  31 7  6*
Insulin secretion
IGI (pmol  mmol
1) 27.7  8.0 16.8  5.5 4.9  0.8† 3.1  1.4*‡
AUCI/AUCG (nmol  mol
1) 38  4.5 42  12.8 22.6  4.5 7.1  3.3*‡
Basal insulin secretion rate (pmol  min
1  m
2) 71  4.8 78  7.6 96  15.0 65  10.1
Glucose sensitivity (pmol  min
1  m
2  mmol
1  l
1) 137  15 106  13 43  20† 22  14*‡
Rate sensitivity (pmol  m
2  mmol
1  l
1) 686  82 1,147  304 493  206 103  50*‡
Ratio of the end and start period potentiation 1.9  0.2 1.4  0.3 1.3  0.4 0.9  0.1*
Disposition index§
Rate sensitivity  whole-body insulin sensitivity (pmol 
min
1  m
4  mol
1  l
1) 853  110 993  340 323  97 67  36*¶
Data are means  SE. Insulin sensitivity (M value) calculated during the steady state of hyperinsulinemic-euglycemic clamp. -cell function
is derived from an oral glucose tolerance test. Comparisons between groups were made when overall P  0.05. A P value for signiﬁcant pairwise
differences is given. *P  0.01 vs. healthy subjects. †P  0.05 vs. healthy subjects. ‡P  0.05 vs. group 1. §Insulin sensitivity per body surface area
multiplied with insulin secretion response to dynamic change in glucose per body surface area (rate sensitivity). ¶P  0.01 vs. group 1.
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had diabetes in OGTT. On the other hand, the -cell
response was markedly decreased in patients with previously
diagnosed diabetes. We also demonstrated a correlation
between insulin secretion and mutation heteroplasmy.
This study showed that the skeletal muscle insulin
sensitivity is decreased in adult subjects with the
m.3243AG mutation. The decrease was similar in sub-
jects with and without overt diabetes, and it resembled
that found in patients with newly diagnosed type 2 diabe-
tes (29). The use of [
18F]FDG and PET enabled us to
measure glucose uptake directly in the skeletal muscle.
Importantly, glucose uptake in muscle measured by this
method is not affected by uptake in the liver or adipose
tissue, whereas such measurements based on whole-body
glucose disposal rate are (33). A standard hyperinsuline-
mic clamp technique has been used in two previous
studies, both including fewer subjects with m.3243AG
than the present study. In one study (18), seven mutation
carriers had lower insulin sensitivity than the control
subjects. However, the authors concluded that peripheral
insulin resistance did not seem to precede diabetes, even
if three of the four subjects with no diabetes had insulin
sensitivity lower than the mean of the control subjects. In
the other study (19), slightly low M values but within
normal range were reported in eight m.3243AG patients
with diabetes and one with impaired glucose tolerance.
However, it is difﬁcult to deduce the contribution of the
m.3243AG mutation to insulin sensitivity from the previ-
ous studies, because the mutation heteroplasmy of the
subjects has not been reported.
The prevalence of m.3243AG has been suggested to be
16 in 100,000 (25), making the recruitment and character-
ization of these patients challenging. Besides sensorineuri-
nal hearing impairment (Table 1), myopathy and exercise
intolerance are rather frequent features among patients
with 3243AG (36). In this study, a structured interview
on physical activity (IPAQ) did not reveal differences in
daily physical activity between the patients and the control
subjects. However, we cannot exclude that the patients
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FIG. 3. Skeletal muscle and whole-body glucose uptake. A: Skeletal
muscle insulin-stimulated glucose uptake. B: Correlation between
skeletal muscle and whole-body glucose uptake (M value) in all groups
(for linear correlation r  0.78–0.99 and P < 0.007). E, control
subjects. Patients with m.3243A>G mutation: F, group 1; Œ, group 2;
and , group 3.
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FIG. 4. Perfusion and glucose extraction in skeletal muscle. A: Skeletal
muscle blood ﬂow per tissue weight. B: Glucose extraction; glucose
uptake per blood ﬂow in skeletal muscle.
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FIG. 5. -Cell function and m.3243A>G heteroplasmy. There was an
inverse relationship between dynamic insulin secretion parameters
and m.3243A>G heteroplasmy. The AUCI/AUCG as a function of
m.3243A>G heteroplasmy in skeletal muscle (r  0.83; P  0.001).
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even if the MRI scans of the calf (data not shown) and the
PET imaging of the thigh did not show signs of it.
Additionally, the m.3243AG mutation has been shown to
lead to impaired endothelial function in brain perfusion
studies with [
15O]H2O PET in severely ill patients (37).
However, we found that the perfusion was normal in
skeletal muscle at rest, suggesting no major participation
of endothelial function in the insulin resistance in patients
with m.3243AG (Fig. 3).
The m.3243AG mutation affects the oxidative phos-
phorylation and ATP production (38), but it is unclear how
mitochondrial dysfunction could induce insulin resistance
in skeletal muscle. Maximal oxidative capacity (Vo2max),
reﬂecting oxidative phosphorylation, correlates with insu-
lin sensitivity in nondiabetic sedentary subjects (38).
Vo2max is also decreased in patients with various mtDNA
mutations at high heteroplasmy levels in skeletal muscle
(39). However, we did not ﬁnd a correlation between
skeletal muscle glucose uptake and m.3243AG mutation
heteroplasmy, suggesting that other factors than the rate
of oxidative phosphorylation might contribute. Low ATP
production and abnormal mitochondrial morphology are
present in skeletal muscle in both type 2 diabetes and in
m.3243AG patients (40,41). Furthermore, insulin-resis-
tant subjects predisposed to type 2 diabetes have been
shown to share some similarities with the m.3243AG
patients, such as low activity of the respiratory chain
enzymes, especially that of Complex I, in skeletal muscle
(36,40–42). Interestingly, a deﬁciency in Complex I activ-
ity increases free radical production (43), which has
recently been shown to impair insulin signaling in mice
(44). Finally, it has recently been shown that insulin
resistance predisposes to the early onset of diabetes in
patients with a primary defect in insulin secretion (45).
Therefore, regardless of its etiology, insulin resistance
might contribute to the very high penetrance of diabetes in
patients with m.3243AG (16).
Previous cross-sectional studies have suggested that
insulin secretion is impaired in patients with m.3243AG
and diabetes, even if the response to arginine and gluta-
mate is preserved (19,20,24). One OGTT study has previ-
ously included more m.3243AG carriers than the present
study (20). It demonstrated that the IGI was decreased in
seven m.3243AG carriers with normal glucose tolerance.
However, in other studies, defects in insulin secretion
have not been found (22,23). We found an inverse relation-
ship between -cell responses and the m.3243AG muta-
tion heteroplasmy. Lack of heteroplasmy data in previous
studies may thus explain the apparently contradicting
results in OGTT studies in m.3243AG patients. Processes
such as oxidative stress, impaired protein synthesis, and
altered autophagy are common in other organs affected by
this mutation (43,46). The onset age of diabetes in patients
with m.3243AG may be determined by a combination of
the mutation load and the degenerative processes leading
to a further decrease in -cell function or mass. Interest-
ingly, a reduced -cell number along with absence of
apoptosis has been reported in the pancreatic tissue of
patients with m.3243AG (47).
It has been proposed that the impaired ATP production
due to the m.3243AG mutation in -cells is followed by
failing K
	 channel opening that leads to decreased insulin
secretion in response to the glucose (38). Low redox state,
low mitochondrial membrane potential, dysfunction of
mitochondrial NADH shuttles, and low complex I activity
could have a similar effect on glucose sensing and insulin
secretion (48). The dysfunction in glucose sensing may
explain the correlation of insulin secretion with tissue
heteroplasmy. However, it fails to explain why none of our
subjects were diabetic in their early lives. It has been
claimed that impaired fatty acid -oxidation in mitochon-
dria may lead to inappropriate storage of triacylglycerols
in the cells and increased free fatty acid and glucose levels
in circulation. The following toxicity in tissues including
the -cells could then induce a decline in the -cell
function in these patients (46). Some of these hypotheses
could partly be compatible with our data and the previous
observations on progressive -cell dysfunction, but they
are based on data obtained from in vitro studies and need
more proof of evidence in clinical studies.
Metabolic effects of mtDNA mutations affecting the respi-
ratory chain have been poorly characterized, although sev-
eral studies have implicated the role of mitochondrial
dysfunction in skeletal muscle insulin resistance, in insulin
secretion, and in the pathogenesis of type 2 diabetes
(7,13). Our results show that both the skeletal muscle
insulin sensitivity and the -cell function are affected
already before the overt diabetic state develops in patients
with the m.3243AG mutation.
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